²»Á¼Ñо¿Ëù

Type 1 diabetes

An image of a group of 5 people sitting and standing around a table talking

 

Every day, people living with serious diseases strive to be more than their disease — to be defined by what they can dream and hope and achieve, not by what limits them. Our commitment to people with serious diseases is uncompromising and goes beyond our research and development (R&D) and medicines. 


 

Working with the type 1 diabetes community

We work with organizations that help people with type 1 diabetes (T1D) live active, full lives.

We are committed to investigating and advancing potential cell therapies aimed at treating T1D. Vertex seeks to identify opportunities where we can support, engage with and learn from people living with T1D and represent the T1D patient voice within Vertex.

An image of a large group of Vertexians attending the JDRF walk representing Team Vertex


Vertexians supporting the 2022 JDRF One Walk.

Engaging with the T1D community

We are proud to work with and support many organizations in the diabetes community including:

 

 

An image of a group of six Vertexians attending the Joslin Diabetes Gala


Vertexians attend the 2023 Joslin Diabetes High Hopes Gala.

Supporting diabetes awareness and education

We're a proud supporter of several of the American Diabetes Association’s State of Diabetes regional programs. The State of Diabetes series brings together diverse stakeholders to address health inequity and inspire solutions and resources to improve diabetes management, prevention and overall health and wellness.  

 

 

A doctor holding a tablet discussing something with an elderly patient
Sponsorships

We were the inaugural sponsor of JDRF’s Clinical Trial Connection Program, an initiative that provides educational resources and connects people living with type 1 diabetes with clinical trials that are actively recruiting participants.

 


 

Learn about our work in type 1 diabetes

To learn more about our type 1 diabetes studies in the U.S., visit the . For information about non-U.S. sites, visit .